Neuromodulation for peripheral neuropathy — spinal cord stimulation, dorsal root ganglion stimulation, and peripheral nerve stimulation providing electrical neuromodulation of nociceptive pathways — has advanced significantly as an interventional option for patients not responding to pharmacological neuropathic pain management, with the Peripheral Neuropathy Market reflecting neuromodulation's growing role in peripheral neuropathy management.

Dorsal root ganglion stimulation for focal neuropathic pain — Abbott Proclaim DRG Neurostimulation System delivering precisely targeted stimulation to DRG neurons providing highly focal pain relief — is particularly effective for complex regional pain syndrome and painful peripheral mononeuropathies with localized distribution. DRG stimulation's advantage over spinal cord stimulation for focal extremity pain has driven adoption for peripheral neuropathy with defined dermatomal distribution that broader SCS field coverage cannot address with equivalent precision.

High-frequency spinal cord stimulation — Nevro Senza HF10 and similar high-frequency stimulation protocols providing paresthesia-free pain relief through sub-threshold stimulation — has demonstrated superior DPN pain outcomes compared to conventional SCS in the SENZA-PDN trial. FDA approval of the Nevro HF10 system specifically for painful diabetic neuropathy based on the SENZA-PDN trial data has established SCS as an evidence-based treatment for refractory DPN unresponsive to pharmacological management.

SENZA-PDN trial significance — demonstrating that HF10 spinal cord stimulation achieved significantly greater pain reduction (seventy-six percent versus five percent) and sustained benefit at twenty-four months compared to conventional medical management for painful DPN — provided the level I evidence that supported both FDA approval and insurer coverage expansion for DPN neuromodulation. The trial's landmark results have generated significant clinical and commercial momentum for neuromodulation in peripheral neuropathy.

Do you think spinal cord stimulation will become a mainstream mid-line treatment option for painful DPN rather than a last-resort intervention after multiple drug failures?

FAQ

What is spinal cord stimulation for diabetic neuropathy? SCS delivers electrical current to the spinal cord through implanted electrodes modulating pain signal transmission; high-frequency (10kHz) SCS provides paresthesia-free pain relief; the SENZA-PDN trial demonstrated dramatically superior outcomes for HF10 versus conventional medical management in painful DPN; FDA cleared the Nevro HF10 system specifically for painful DPN based on this evidence.

What is dorsal root ganglion stimulation? DRG stimulation delivers electrical stimulation directly to the dorsal root ganglion — the sensory neuron cell body cluster — providing highly targeted paresthesia coverage for focal painful conditions including CRPS, painful peripheral mononeuropathies, and post-amputation pain; Abbott Proclaim DRG system is FDA-approved for lower limb CRPS and provides more focal coverage than conventional SCS.

#PeripheralNeuropathy #SpinalCordStimulation #DRGstimulation #NevroHF10 #SENZApdnTrial #DPNneuromodulation